![](/img/cover-not-exists.png)
PCN101 COST-UTILITY ANALYSIS OF DASATINIB AS A SECOND-LINE TREATMENT IN THE CHRONIC PHASE OF CHRONIC MYELOID LEUKAEMIA IN RUSSIA
S Kuznetzov, LJ Mungapen, Y Samyshkin, DE Jakouloff, U Sbarigia, M van BaardewijkVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)71996-9
File:
PDF, 76 KB
english, 2010